Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
Vericel (NASDAQ:VCEL) announced it will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026.
Rhea-AI Summary
Vericel (NASDAQ:VCEL) announced it will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026. A live webcast of the presentation will be accessible through the Investor Relations section of Vericel's website at http://investors.vcel.com.
Positive
- None.
Negative
- None.
Details
News Market Reaction – VCEL
In the Jun 9 session, VCEL gained 3.52%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Share price
- $35.77
- Pre-news current price for VCEL
- Volume today
- 371,967 shares
- Compared with 20-day average volume
- Avg 20-day volume
- 581,325 shares
- Liquidity benchmark before this news
- 52-week high
- $45.97
- Upper end of 52-week trading range
- 52-week low
- $28.95
- Lower end of 52-week trading range
- Market cap
- $1,853,776,676
- Equity value prior to conference announcement
- Conference date
- June 16, 2026
- Truist Securities MedTech Conference presentation
- Publication date
- June 9, 2026
- Date conference participation was announced
Historical Context
-
Strong Q1 growth and raised 2026 revenue guidance.
-
Announcement of Q1 2026 results date and call details.
-
Ten-year BARDA award up to $197M for NexoBrid.
-
FDA approval for new MACI manufacturing facility in Burlington.
-
Planned presentations at March 2026 healthcare conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. ©2026 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.